AFT Stock Overview
Engages in the development and sale of pharmaceutical products in New Zealand, Australia, Asia, and internationally. More details
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for AFT from our risk checks.
AFT Pharmaceuticals Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NZ$2.65 |
52 Week High | NZ$3.85 |
52 Week Low | NZ$2.37 |
Beta | 0.37 |
11 Month Change | -20.18% |
3 Month Change | -18.71% |
1 Year Change | -20.90% |
33 Year Change | -45.25% |
5 Year Change | -15.06% |
Change since IPO | -14.52% |
Recent News & Updates
AFT Pharmaceuticals Limited (NZSE:AFT) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Nov 17It's Unlikely That The CEO Of AFT Pharmaceuticals Limited (NZSE:AFT) Will See A Huge Pay Rise This Year
Jul 26Recent updates
AFT Pharmaceuticals Limited (NZSE:AFT) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Nov 17It's Unlikely That The CEO Of AFT Pharmaceuticals Limited (NZSE:AFT) Will See A Huge Pay Rise This Year
Jul 26AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates
May 25Does AFT Pharmaceuticals (NZSE:AFT) Deserve A Spot On Your Watchlist?
May 22Is Now The Time To Put AFT Pharmaceuticals (NZSE:AFT) On Your Watchlist?
Oct 17Should You Be Adding AFT Pharmaceuticals (NZSE:AFT) To Your Watchlist Today?
May 23Is AFT Pharmaceuticals Limited (NZSE:AFT) Trading At A 50% Discount?
Dec 01We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise
Jul 30With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For
Jun 02Should You Be Impressed By AFT Pharmaceuticals Limited's (NZSE:AFT) ROE?
Mar 20A Quick Analysis On AFT Pharmaceuticals' (NZSE:AFT) CEO Compensation
Feb 13Are AFT Pharmaceuticals's (NZSE:AFT) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Jan 23Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?
Jan 02Should AFT Pharmaceuticals (NZSE:AFT) Be Disappointed With Their 89% Profit?
Dec 12AFT Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Nov 21Shareholder Returns
AFT | NZ Pharmaceuticals | NZ Market | |
---|---|---|---|
7D | 6.9% | -11.4% | 0.1% |
1Y | -20.9% | 34.7% | 9.6% |
Return vs Industry: AFT underperformed the NZ Pharmaceuticals industry which returned 34.7% over the past year.
Return vs Market: AFT underperformed the NZ Market which returned 9.6% over the past year.
Price Volatility
AFT volatility | |
---|---|
AFT Average Weekly Movement | 4.8% |
Pharmaceuticals Industry Average Movement | 11.9% |
Market Average Movement | 4.5% |
10% most volatile stocks in NZ Market | 9.3% |
10% least volatile stocks in NZ Market | 3.0% |
Stable Share Price: AFT has not had significant price volatility in the past 3 months compared to the NZ market.
Volatility Over Time: AFT's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 110 | Hartley Atkinson | www.aftpharm.com |
AFT Pharmaceuticals Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical products in New Zealand, Australia, Asia, and internationally. It offers products for use in the areas of allergy, gastrointestinal, cold and flu, digestive health, eye care, first aid, nail care, oral care, pain management, skin care, vitamins, and supplements, as well as other products. AFT Pharmaceuticals Limited was incorporated in 1997 and is headquartered in Auckland, New Zealand.
AFT Pharmaceuticals Limited Fundamentals Summary
AFT fundamental statistics | |
---|---|
Market cap | NZ$274.75m |
Earnings (TTM) | NZ$15.61m |
Revenue (TTM) | NZ$195.41m |
17.8x
P/E Ratio1.4x
P/S RatioIs AFT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AFT income statement (TTM) | |
---|---|
Revenue | NZ$195.41m |
Cost of Revenue | NZ$107.14m |
Gross Profit | NZ$88.27m |
Other Expenses | NZ$72.66m |
Earnings | NZ$15.61m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.15 |
Gross Margin | 45.17% |
Net Profit Margin | 7.99% |
Debt/Equity Ratio | 32.1% |
How did AFT perform over the long term?
See historical performance and comparison